This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a study of postmenopausal women at increased risk for breast cancer who are randomized to either Tamoxifen or Raloxifene to determine which is most effective with the least amount of side effects.Evidence from a large clinical trial shows that tamoxifen helps to reduce the incidence of breast cancer in women who are at increased risk for developing the disease. The U.S. Food and Drug Administration (FDA) has approved tamoxifen for such use. Raloxifene has been approved by the FDA and the Canadian Health Protection Branch (HPB) for the prevention of osteoporosis (thinning of bones) in postmenopausal (women who have stopped menstruating). Researchers think raloxifene may also reduce the risk of developing breast cancer and have fewer side effects than tamoxifen. The FDA and the HPB consider the use of raloxifene for reducing the risk of breast cancer to be experimental at this time.
Showing the most recent 10 out of 535 publications
